Market Place
Sourcing Support
Cantargia Shows Nadunolimab Data In Triple Negative Breast Cancer
11 Dec 2024 //
ACCESSWIRE
Extraordinary General Meeting in Cantargia AB (publ)
02 Dec 2024 //
ACCESSWIRE
Cantargia Expands CAN10 Ph 1 Clinical Program With Positive Results
29 Nov 2024 //
ACCESSWIRE
Cantargia Publishes Interim Report for Third Quarter 2024
15 Nov 2024 //
ACCESSWIRE
Cantargia Presents Nomination Committee Ahead of 2025 AGM
13 Nov 2024 //
ACCESSWIRE
Cantargia Publishes CAN10 Efficacy in Myocarditis Models
11 Nov 2024 //
ACCESSWIRE
Notice of extraordinary general meeting in Cantargia AB (publ)
06 Nov 2024 //
ACCESSWIRE
Cantargia Presents on Nadunolimab With ADC at Oncology Conference
05 Nov 2024 //
ACCESSWIRE
Cantargia Reports Nadunolimab Results in Cancer Studies
28 Oct 2024 //
ACCESSWIRE
Cantargia Reports Results on Biomarkers and Safety in CAN10 Ph1 Study
11 Oct 2024 //
ACCESSWIRE
Cantargia`sPh 2 Nadunolimab Data Published In Cancer Research
10 Oct 2024 //
ACCESSWIRE
Cantargia Shows Nadunolimab Benefit After PD1-Inhibitor Relapse At ESMO
14 Sep 2024 //
ACCESSWIRE
Cantargia: New Data Support Nadunolimab Efficacy
08 Sep 2024 //
ACCESSWIRE
Cantargia Reports Timelines For Nadunolimab Trials In Leukemia And Cancer
27 Aug 2024 //
ACCESSWIRE
Cantargia Presents Preclinical Data Supporting CAN10 In Lung Fibrosis
27 Aug 2024 //
ACCESSWIRE
Cantargia Reports Progress In CAN10 Phase I Trial
09 Aug 2024 //
ACCESSWIRE
Cantargia presents Phase 2 Data in Pancreatic Cancer with Nadunolimab at ESMO
20 Jun 2024 //
ACCESSWIRE
Cantargia Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10
14 Jun 2024 //
ACCESSWIRE
Cantargia Appoints Ton Berkien As Chief Business Officer
12 Jun 2024 //
ACCESSWIRE
Annual General Meeting in Cantargia AB (publ)
23 May 2024 //
ACCESSWIRE
Cantargia Publishes Interim Report for the First Quarter of 2024
21 May 2024 //
ACCESSWIRE
Cantargia Q1 Report Presentation On May 21
07 May 2024 //
ACCESSWIRE
Notice of Annual General Meeting in Cantargia AB (publ)
18 Apr 2024 //
ACCESSWIRE
Cantargia Publishes Annual Report for 2023
18 Apr 2024 //
ACCESSWIRE
Cantargia Publishes Data on the CAN10, Detailing its Interaction with IL1RAP
17 Apr 2024 //
ACCESSWIRE
Cantargia Publishes CAN10 Systemic Sclerosis Preclinical Data
10 Apr 2024 //
ACCESSWIRE
Cantargia Presents Unique Effects of Nadunolimab in Pancreatic Cancer
08 Apr 2024 //
ACCESSWIRE
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis
02 Apr 2024 //
ACCESSWIRE
Cantargia Reports Progress Towards Start the Trial of Nadunolimab in Leukemia
27 Mar 2024 //
ACCESSWIRE
Cantargia Reports Regulatory Approval to Start Phase IIb Trial with Nadunolimab
20 Feb 2024 //
ACCESSWIRE
Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy
12 Feb 2024 //
ACCESSWIRE
Invitation to Presentation of Cantargia’s Year-End Report 2023
07 Feb 2024 //
ACCESSWIRE
Cantargia Reports Phase I Clinical Progress in the CAN10 Project
09 Jan 2024 //
ACCESSWIRE
Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab
24 Nov 2023 //
ACCESSWIRE
Cantargia Publishes Interim Report for Third Quarter 2023
10 Nov 2023 //
ACCESSWIRE
Cantargia to host R&D Day on results of nadunolimab in pancreatic cancer
04 Apr 2023 //
PR NEWSWIRE
Cantargia presents positive results for nadunolimab at AACR
14 Mar 2023 //
PR NEWSWIRE
Cantargia treats breast cancer patient in randomized PII part of TRIFOUR trial
14 Mar 2023 //
PR NEWSWIRE
Cantargia publishes full year report for 2022
23 Feb 2023 //
PR NEWSWIRE
Invitation to presentation of Cantargia`s Year-end report of 2022 on February 23
14 Feb 2023 //
PR NEWSWIRE
Cantargia announces appointment of Patrik Renblad as Chief Financial Officer
01 Feb 2023 //
PR NEWSWIRE
Cantargia completes toxicity study of CAN10 antibody
16 Jan 2023 //
CLINICAL TRIALS ARENA
Cantargia successfully concludes toxicity study with CAN10 antibody
13 Jan 2023 //
PR NEWSWIRE
Cantargia: Nomination Committee appointed ahead of 2023 Annual General Meeting
21 Nov 2022 //
PRNEWSWIRE
Cantargia publishes interim report for third quarter 2022
10 Nov 2022 //
PRNEWSWIRE
Cantargia`s CAN10 demonstrates positive activity in systemic sclerosis models
08 Nov 2022 //
CISION
Cantargia presents new data supporting nadunolimab`s promising efficacy
07 Nov 2022 //
PRNEWSWIRE
Cantargia reaches recruitment milestone and focuses nadunolimab development
14 Oct 2022 //
PRNEWSWIRE
Cantargia: Oral presentation of new preclinical CAN10 efficacy data
15 Sep 2022 //
CISION
Cantargia presents preclinical data demonstrating effects of nadunolimab
14 Sep 2022 //
CISION
Cantargia completes patient recruitment in the CANFOUR study
10 Sep 2021 //
CISION
Cantargia receives regulatory approval to start CESTAFOUR clinical study
10 Sep 2021 //
CISION
Cantargia expands nadunolimab development in NSCLC
06 Sep 2021 //
PRNEWSWIRE
Cantargia reports first patient treated in CAPAFOUR study
26 Aug 2021 //
CISION
Cantargia broadens the development of nadunolimab
29 Jun 2021 //
PRNEWSWIRE
Cantargia receives approval to start trial for nadunolimab & FOLFIRINOX
08 Jun 2021 //
PRNEWSWIRE
Cantargia reports positive results in ongoing phase IIa clinical trial
18 May 2021 //
PRNEWSWIRE
Cantargia submits application to start new clinical trial investigating
09 Mar 2021 //
PRNEWSWIRE
BioInvent and Cantargia sign MFG agreement for monoclonal antibody CAN10
25 Nov 2020 //
MEDICIRCLE
